Samarth Kulkarni - 13 Oct 2025 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role: Chief Executive Officer, Director
Signature: /s/ Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol: CRSP
Transactions as of: 13 Oct 2025
Net transactions value: -$282,517
Form type: 4
Filing time: 15 Oct 2025, 17:35:05 UTC
Previous filing: 03 Oct 2025
Next filing: 20 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kulkarni Samarth	Chief Executive Officer, Director	C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	15 Oct 2025	0001682019

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRSP	Common Shares	Options Exercise		+8,334	+4.1%		209,338	13 Oct 2025	Direct	F1
transaction	CRSP	Common Shares	Sale	$282,517	-4,242	-2%	$66.60	205,096	14 Oct 2025	Direct	F2
holding	CRSP	Common Shares						85,662	13 Oct 2025	The Kulkarni 2023 GRAT

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRSP	Restricted Stock Units	Options Exercise		-8,334	-50%		8,333	13 Oct 2025	Common Shares	8,334		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2	Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3	This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.